Biography
Genetika+ is focused on personalizing treatment in the mental health space, with a first product focusing on optimizing drug choice in depression. Prior to co-founding Genetika+ , Daphna was Chief Scientific Officer at Ibex Medical Analytics, a digital health company developing AI-based cancer diagnostics, and before that, she served as Head, Personalized Medicine and Diagnostics at Teva Pharmaceuticals, where she supported the discovery, development and differentiation of Teva’s pipeline drugs, in collaboration with the Israeli healthcare sector and multinational companies. Daphna joined Teva after having led biomarker and diagnostic development activities within the pipeline of multiple top-10 pharma and fortune 500 companies. She served in several roles with increasing responsibility at Selventa, a system's biology company focused on personalized medicine, and founded the Israeli branch of the company, as Global Head of Diagnostics. Daphna trained as post-doc at Harvard University, after receiving her PhD in Medical Sciences from the Technion.

Clinical Dx Showcase:
Genetika+
Genetika+ personalizes treatment in the mental health space, initially focusing on depression. The Genetika+ platform uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Brain in a Dish: Personalizing Treatment in Depression
Major depression is a leading cause of health-related burden globally, further exacerbated by Covid-19. Despite the availability of many antidepressant on the market, most patients do not effectively respond to the prescribed treatment. Genetika+’s RxMine platform converts patients' blood cells into neurons, which in turn are used to screen for the optimal drug for each individual. By combining the patient’s genetics and medical history into an AI-based algorithm, a tailored report describes the optimal drug for each patient.